Andy Hsieh
Stock Analyst at William Blair
(3.99)
# 1,780
Out of 5,005 analysts
358
Total ratings
43.7%
Success rate
6.6%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TLX Telix Pharmaceuticals | Reiterated: Buy | n/a | $11.62 | - | 1 | Sep 22, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $33.03 | - | 40 | Sep 22, 2026 | |
| CATX Perspective Therapeutics | Initiated Coverage: Buy | n/a | $2.50 | - | 1 | Sep 18, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | n/a | $6.92 | - | 17 | Sep 14, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Hold | n/a | $1.20 | - | 19 | Sep 14, 2026 | |
| EXEL Exelixis | Reiterated: Buy | n/a | $58.37 | - | 60 | Sep 11, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Hold | n/a | $2.90 | - | 12 | Sep 9, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | n/a | $35.07 | - | 12 | Sep 8, 2026 | |
| KYNB Kyntra Bio | Reiterated: Hold | n/a | $6.90 | - | 29 | Aug 31, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | n/a | $46.01 | - | 2 | Aug 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $60.40 | - | 31 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.27 | - | 6 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.96 | - | 12 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.22 | - | 11 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.12 | - | 5 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $99.74 | - | 18 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $7.18 | - | 14 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.5898 | - | 5 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.61 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.365 | n/a | 8 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.18 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.12 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $152.21 | n/a | 1 | Feb 12, 2019 |
Telix Pharmaceuticals
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.62
Upside: -
Viking Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $33.03
Upside: -
Perspective Therapeutics
Sep 18, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $2.50
Upside: -
Corbus Pharmaceuticals Holdings
Sep 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.92
Upside: -
Cardiff Oncology
Sep 14, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.20
Upside: -
Exelixis
Sep 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $58.37
Upside: -
Pyxis Oncology
Sep 9, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.90
Upside: -
Structure Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $35.07
Upside: -
Kyntra Bio
Aug 31, 2026
Reiterated: Hold
Price Target: n/a
Current: $6.90
Upside: -
Enliven Therapeutics
Aug 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $46.01
Upside: -
Aug 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $60.40
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.27
Upside: -
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.96
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.22
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.12
Upside: -
Aug 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $99.74
Upside: -
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $7.18
Upside: -
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.5898
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.61
Upside: -
Jul 23, 2025
Rated: Hold
Price Target: n/a
Current: $0.365
Upside: n/a
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $1.18
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $1.12
Upside: n/a
Feb 12, 2019
Reiterated: Buy
Price Target: n/a
Current: $152.21
Upside: n/a